Back to Search
Start Over
Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2019 Mar 01; Vol. 58 (5), pp. 707-712. Date of Electronic Publication: 2018 Nov 19. - Publication Year :
- 2019
-
Abstract
- A 45-year-old woman was diagnosed with hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma. She received different types of chemotherapy, but disease progression was observed. To reduce the tumor burden before an unrelated bone marrow transplantation, combination chemotherapy consisting of the gemcitabine, carboplatin, and dexamethasone (GCD) was administered as bridging therapy, resulting in a reduction in the number of lymphoma cells. We were then able to perform bone marrow transplantation. Although she experienced some adverse events, she successfully achieved long-term remission. We herein report a successful case of HSTCL treated with unrelated stem cell transplantation following the GCD regimen as bridging chemotherapy.
- Subjects :
- Carboplatin administration & dosage
Combined Modality Therapy methods
Deoxycytidine administration & dosage
Deoxycytidine analogs & derivatives
Dexamethasone administration & dosage
Female
Humans
Middle Aged
Gemcitabine
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Hematopoietic Stem Cell Transplantation methods
Liver Neoplasms therapy
Lymphoma, T-Cell, Peripheral therapy
Splenic Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 58
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 30449784
- Full Text :
- https://doi.org/10.2169/internalmedicine.1266-18